+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Opioid (Opium) Addiction Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials

  • ID: 5464027
  • Report
  • November 2021
  • Region: Global
  • 70 Pages
  • VPA Research
UP TO OFF until Jun 15th 2022
Opioid (Opium) Addiction pipeline drugs and companies, 2021- Phase, Mechanism of Action, Route, Licensing/collaboration, pre-clinical and clinical trials

The global comprehensive report on “Opioid (Opium) Addiction pipeline drugs and companies” presents key-decision makers with critical insights into Opioid (Opium) Addiction pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

Opioid (Opium) Addiction pipeline Drug Snapshot, 2021


The Opioid (Opium) Addiction pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Opioid (Opium) Addiction. In addition to recent status, overview of drugs is included in the study. Wide range of Opioid (Opium) Addiction drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

Opioid (Opium) Addiction drug development pipeline by phase


The Opioid (Opium) Addiction pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all Opioid (Opium) Addiction pipeline candidates is provided in the report enables you to understand timetable developments in Opioid (Opium) Addiction therapeutic area.

Opioid (Opium) Addiction pipeline drug Technology, Licensing and Collaboration Details


Details of technologies used for development of Opioid (Opium) Addiction pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the Opioid (Opium) Addiction research study. Companies looking to partner with other players are also detailed in the report.

Opioid (Opium) Addiction- mechanism of action of pipeline candidates


Opioid (Opium) Addiction pipeline guide details the mechanism of action of each of the drug candidate under development. Further, leading types of mechanism of action (MoA) targeted by different Opioid (Opium) Addiction companies are identified to support decision makers target the most potential drugs under development.

Further, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of Opioid (Opium) Addiction drug administration.

Opioid (Opium) Addiction Drugs- Preclinical and Clinical Trials


This chapter in Opioid (Opium) Addiction preclinical and clinical trials assists in gaining clear understanding of the timetable developments in Opioid (Opium) Addiction product area. Preclinical and clinical trial details of pipeline candidates for Opioid (Opium) Addiction are detailed in the report. Details including participants, duration, companies, locations and others are provided for the trials.

Opioid (Opium) Addiction companies and Profiles


Companies developing Opioid (Opium) Addiction pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

Opioid (Opium) Addiction Market Developments


The report presents the recent news and developments in the Opioid (Opium) Addiction pipeline industry. Progress of candidates, mergers, acquisitions, asset transactions, licensing, collaborations, partnership and joint ventures, regulatory approvals, marketing and other relevant news and deals are discussed in the report.

Reasons to Buy

  • Make better-informed decisions based on the current status of each of the pipeline drug candidate
  • Identify new business opportunities by evaluating the progress of the Opioid (Opium) Addiction R&D pipeline
  • Analyze the market and research segments based on a comprehensive analysis of Opioid (Opium) Addiction pipeline drugs and clinical trials
  • Identify Opioid (Opium) Addiction drug pipeline trends based on consistently delivered hands on pipeline and clinical trials information
  • Gain clear understanding of the Opioid (Opium) Addiction drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
  • Check the Opioid (Opium) Addiction pipeline progress of target companies and key strategies of leading players
  • Gain real-time insights into the global Opioid (Opium) Addiction pipeline news, developments and insights

Scope of the Report

  • Disease overview including Opioid (Opium) Addiction symptoms, widely used treatment options, companies and other details are included
  • Opioid (Opium) Addiction Pipeline Summary including the dominant phase type, number of drug candidates progressing to advanced phases, early stage pipeline candidates, leading companies, dominant route of mechanism and route of administration and other details are provided.
  • Opioid (Opium) Addiction pipeline drug count by phase, company and mechanism of action
  • Opioid (Opium) Addiction companies investing R&D resources in pipeline
  • Dominant Mechanism of Action
  • Most researched route of administration
  • For each pipeline candidate, drug, originator, co-developers, other companies, special status, phase, synonym, current status and other details are included
  • Clinical trial information for each Opioid (Opium) Addiction pipeline candidate are provided including preclinical, phase 1, phase 2 and phase 3 details
  • Opioid (Opium) Addiction companies including their business snapshot, business description and Opioid (Opium) Addiction pipelines are included.
  • Recent Opioid (Opium) Addiction market developments, pipeline news and deals are provided
Note: Product cover images may vary from those shown

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Executive Summary
2.1 Opioid (Opium) Addiction Disease overview
2.2 Companies investing in Opioid (Opium) Addiction industry
3 Opioid (Opium) Addiction Pipeline Snapshot, 2021
3.1 Opioid (Opium) Addiction Pipeline Drugs- Dominant phase type
3.2 Opioid (Opium) Addiction pipeline Drugs- Leading Mechanism of Action
3.3 Opioid (Opium) Addiction Pipeline Drugs- Widely researched Route of Administration
3.4 Opioid (Opium) Addiction Pipeline- New Molecular Entity
3.5 Opioid (Opium) Addiction pipeline- Companies, Universities and Institutes
4. Opioid (Opium) Addiction Drug Profiles
4.1 Current Status of Opioid (Opium) Addiction Drug Candidates, 2021
4.2 Opioid (Opium) Addiction Drugs in Development- Originator/Licensor
4.3 Opioid (Opium) Addiction Drugs in Development- Route of Administration
4.4 Opioid (Opium) Addiction Drugs in Development- New Molecular Entity (NME)
5. Opioid (Opium) Addiction Clinical Trials
5.1 Preclinical Trial details
5.2 Phase 1 Clinical Trial Details
5.3 Phase 2 Clinical Trial Details
5.4 Phase 3 Clinical Trial Details
6. Opioid (Opium) Addiction Companies and Universities
6.1 Leading Opioid (Opium) Addiction companies researching in drug development
6.2 Leading Opioid (Opium) Addiction Universities/Institutes investing in drug development
7. Opioid (Opium) Addiction News and Deals
7.1 Recent Opioid (Opium) Addiction Market Developments
7.2 Pipeline Drug News Updates
7.3 Pipeline Company updates
8. Appendix
8.1 Sources and Research Methodology
8.2 Online Database
8.3 Primary and Secondary Methodology
8.4 Customization options
8.5 Contact
Note: Product cover images may vary from those shown